Cyclophosphamide
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Shanghai Jiao Tong University School of MedicineSmall moleculePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 66/ 100
- Competitive Position
- 89/ 100
Competitive context
58 Active assets in the Primary Cutaneous T-Cell Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Dexasone National Cancer Institute (NCI) | Phase 2 | BBB |
Bexarotene Case Comprehensive Cancer Center | Phase 4 | BBB |
Nivestim City of Hope Medical Center | Phase 4 | BBB |
Adriamycin Falo, Louis, MD | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →